/

NNVC

NanoViricides, Inc.Closed

1.32+0.04 +3.13%USD

NYSE American · as of Oct 13, 16:00 ETAfter hours 1.31 −0.85%

Open

1.24

Prev close

1.28

Day range

1.241.34

52-week range

0.85002.23

Volume

237.42K0.55×

Mkt cap

33.69M

P/E ttm

—

Fwd P/E

-3.77

EPS ttm

-0.4100

Div yield

0.00%

Earnings

—

From 52w high

−40.81%

Price Chart

Yahoo Finance · delayed

NNVCOct 13, 2026O 1.24H 1.34L 1.24C 1.32+0.04 (+3.13%)Vol 224.00K

SMA 501.31
SMA 2001.28

1Y change −2.94% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

NNVC NanoViricides, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.71%
1 month: +29.41%
3 months: −25.42%
6 months: +26.92%
Year to date: +16.81%
1 year: −2.94%

Valuation & ownership

Market cap: 33.69M
Enterprise value: 30.90M
P/E (ttm): —
Forward P/E: -3.77
PEG ratio: —
Price / book: 3.50
Price / sales (ttm): —
EV / EBITDA: -3.97
EPS (ttm): -0.4100
EPS (forward): -0.3500
Beta (5y monthly): 1.79
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 25.52M
Float: 24.92M
Short % of float: 3.71%
Short ratio (days): 1.40
Held by insiders: 2.49%
Held by institutions: 9.29%
Avg volume (3m): 429.15K
50-day average: 1.32
200-day average: 1.28
52-week change: −2.94%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 49.0
vs 50-day SMA: +0.58%
vs 200-day SMA: +3.46%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 9.11%
Realised vol (20d, ann.): 132.8%
From 52-week high: −40.81%
From 52-week low: +55.29%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

6.00

+354.55% implied

Low 6.00Median 6.00High 6.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0
2m ago

DES

About NanoViricides, Inc.

Yahoo Finance profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Sector: Healthcare
Industry: Biotechnology
Employees: 7
Headquarters: Shelton, CT, United States
Website: nanoviricides.com

SEAS

Seasonality · NNVC

2007–2026 · monthly returns

Strongest month Jan +37.89%Weakest month Dec −8.15%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-14.2	8.2	-13.3	36.3	43.5	-22.5	10.1	-17.8	4.0	1.5			+16.8%
2025	-16.1	10.0	-11.4	17.1	10.9	-7.9	15.7	-14.2	2.9	16.1	-26.5	-7.4	−21.0%
2024	8.8	21.6	-14.1	3.4	100.0	-28.3	26.7	-10.6	-23.1	-4.7	-4.9	5.1	+40.2%
2023	27.9	-2.8	-15.2	13.7	-21.1	9.5	34.8	-6.5	-7.6	-15.7	1.8	-11.3	−8.1%
2022	-36.3	-19.8	10.0	-28.7	34.2	-6.0	-3.2	31.3	-27.6	-0.6	-7.6	-30.2	−70.2%
2021	40.8	3.5	12.9	-12.1	-13.5	29.2	-13.4	-3.7	19.9	2.2	-0.4	-21.2	+29.6%
2020	567.7	-43.3	-39.6	4.5	25.3	-0.5	-16.6	-36.4	-3.3	-10.2	13.3	-26.6	+14.3%
2019	50.0	26.7	-28.9	-7.4	12.0	-14.3	-8.3	-4.5	-51.2	2.9	30.8	-9.1	−37.3%
2018	1.1	3.4	-10.9	-14.6	-20.0	-21.4	-11.4	7.7	-14.3	-11.1	15.6	-45.9	−77.3%
2017	7.5	3.5	-5.9	9.8	0.0	9.8	5.9	-4.9	-16.2	-7.0	-2.8	-14.6	−17.8%
2016	17.8	79.9	-12.4	-22.4	12.9	-16.7	9.4	-13.7	11.9	-13.6	-21.2	-7.0	−9.3%
2015	-4.4	1.5	-14.8	-23.6	-9.9	11.6	-13.3	-20.7	0.0	1.7	0.8	-3.3	−56.6%
2014	-4.6	-13.1	-19.6	-0.6	11.3	19.5	-4.0	-3.4	-23.5	27.0	-16.0	-15.0	−43.3%
2013	2.1	0.0	31.3	-7.9	8.6	11.1	24.3	39.1	22.6	4.4	-9.6	-2.0	+191.8%
2012	1.6	11.1	1.4	-18.3	15.5	-16.4	-8.9	27.5	1.5	-10.6	-15.3	-6.0	−24.2%
2011	-12.2	-10.1	7.8	6.4	11.3	-18.9	-2.5	-6.8	-11.0	3.1	-34.0	-6.1	−57.8%
2010	21.2	31.1	25.9	44.7	-29.7	4.0	-26.1	-21.8	-3.8	4.0	26.9	11.4	+72.9%
2009	-12.3	0.0	-4.2	17.6	-23.7	-9.8	38.2	17.1	-7.9	-1.2	6.2	-1.2	+4.9%
2008	2.6	47.5	-8.5	24.1	80.6	14.0	-20.3	12.7	-31.5	-11.8	-18.7	32.8	+107.7%
2007	56.8	-12.9	17.8	0.0	-11.8	-12.4	-3.3	-47.2	57.4	-23.0	-33.3	2.6	−47.3%

13F

Investors Holding NNVC

latest 13F filings of 29 followed managers

Investors holding NNVC
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$177.5K	0.00%	128.60K	−4.7%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

NNVC

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

NNVC

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NanoViricides, Inc.

Seasonality · NNVC

Insider Activity · NNVC

Congress Trades · NNVC

Investors Holding NNVC

Investors Holding NNVC

Congress Trades · NNVC

Insider Activity · NNVC

Seasonality · NNVC

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About NanoViricides, Inc.

Financial Snapshot

Earnings & Dividends

News